Selloff? What Selloff? Monday Market Rebound

U.S. equities staged a strong rebound on Monday, with major indices gaining over 1.3%, as bond yields remained steady and June Factory Orders, while negative, surpassed expectations at -4.8%. Palantir Technologies (PLTR) reported robust Q2 results, with revenues hitting a record $1.0 billion and raised guidance, boosting shares 4%. Conversely, Hims & Hers Health (HIMS) missed Q2 estimates, leading to a 12% aftermarket decline, and Vertex Pharmaceuticals (VRTX) fell 13.5% despite beating estimates, due to a failed Phase 2 drug and executive departure. The week ahead features a busy Q2 earnings calendar and key economic data releases.

Analysis

The market demonstrated a strong risk-on sentiment to begin the week, with major indices posting significant gains that reversed the prior session's losses. The Nasdaq led the advance with a 1.95% increase, followed by the Russell 2000 at 2.05%, indicating broad-based strength. This rally was supported by stable bond yields, with the 10-year at 4.20%, reinforcing market expectations for a potential Federal Reserve rate cut at its September 17th meeting. On the economic front, June Factory Orders contracted by 4.8%, a figure that, while negative, was better than consensus and followed a record, upwardly revised 8.3% gain in the previous month, suggesting a normalization from tariff-related distortions. After-hours earnings reports presented a divergent picture of corporate health. Palantir Technologies (PLTR) delivered a standout quarter, with record revenues of $1.0 billion surpassing estimates of $938.3 million, driven by strong growth in its U.S. (+68%), commercial (+93%), and government (+53%) segments. The company's substantially raised revenue guidance for the upcoming quarter and full year propelled its shares up 4% in late trading. In stark contrast, Hims & Hers Health (HIMS) missed on both revenue and earnings estimates, causing a 12% share price decline despite reaffirming full-year guidance. Similarly, Vertex Pharmaceuticals (VRTX) shares fell 13.5% as the discontinuation of a Phase 2 drug and the departure of its Chief Scientific Officer overshadowed an earnings and revenue beat, highlighting the critical importance of pipeline developments in the biopharma sector.

Key Decisions for Investors

• Given Palantir's record revenue, significant guidance raise, and broad-based segment strength, investors should assess if the positive catalysts fully justify its valuation and long-term 10x growth ambition.
• The sharp post-earnings declines in Hims & Hers and Vertex Pharmaceuticals serve as a reminder that fundamentals and forward-looking catalysts can heavily outweigh headline performance; the 13.5% drop in VRTX, despite an earnings beat, underscores the high-stakes nature of clinical trial outcomes in biotech.
• While the market rally reflects renewed optimism, investors should monitor upcoming economic releases, such as the U.S. Trade Deficit and Services PMI, as these data points will be critical inputs for the Federal Reserve's next interest rate decision in September.
• The mixed after-hours results signal a discerning market, suggesting investors should prioritize individual company fundamentals and guidance over broad market momentum, especially with a heavy slate of earnings from bellwethers like CAT, MCD, and AMD scheduled.